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The integrin α6β4 (referred to as β4) is expressed in epithelial cells where it 
functions as a laminin receptor. Integrin β4 is important for the organization and 
maintenance of epithelial architecture in normal cells. Particularly, β4 is shown to 
be essential for mammary gland development during embryogenesis. Integrin β4 
also plays important roles in tumor formation, invasion and metastasis in breast 
cancer. However, the mechanism of how integrin β4 mediates breast tumor 
formation has not been settled. A few studies suggest that integrin β4 is involved 
in cancer stem cells (CSCs), but the mechanism is not clear. To address this 
problem, I examined the expression of β4 in breast tumors and its potential role 
involved in regulating CSCs. My data shows that β4 is expressed 
heterogeneously in breast cancer, and it is not directly expressed in CSCs but 
associated with a basal epithelial population. This work suggests that β4 can 
regulate CSCs in a non-cell-autonomous manner through the interactions 
between β4+ non-CSC population and β4- CSC population. My data also shows 
that β4 expression is associated with CD24+CD44+ population in breast tumor. 
To further study the role of β4 in breast cancer progression, I generated a β4 
reporter mouse by inserting a p2A-mCherry cassette before ITGB4 stop codon. 
This reporter mouse can be crossed with breast tumor models to track β4+ 
population during tumor progression. 
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This thesis focuses on the role of integrin α6β4 in cancer stem cells and tumor 
initiation in breast cancer. This issue is significant because integrin α6β4 as an 
adhesion receptor is important for organization and maintenance of epithelial 
architecture. It also can mediate a variety of signaling pathways to promote tumor 
progression (Soung et al., 2011). 
 
Breast Cancer Overview 
Breast cancer is a major health problem and the most commonly diagnosed 
cancer in women worldwide. The American Cancer Society estimates that about 
231,840 new cases of female invasive breast cancer and 60,290 new cases of 
breast carcinoma in situ will be diagnosed in 2015 (Siegel et al., 2015). Breast 
cancer alone is expected to account for 29% of all new cancers among women in 
the United States (Siegel et al., 2015). It is also the second leading cause of 
cancer death in the United States, with about 40,290 deaths expected in 2015 for 
women representing 15% of all cancer-related deaths among women (Siegel et 
al., 2015). 
 
It is believed that breast cancer develops stepwise from normal breast epithelial 
cells to atypical hyperplasia, ductal carcinoma in situ (DCIS), invasive ductal 
					2	
carcinoma and metastatic breast cancer. Multiple genetic and epigenetic 
alterations may occur during this process. DCIS, though noninvasive, is greatly 
associated with invasive breast cancer and has a very high chance to develop 
into invasive breast cancer if at high grade (Allred, 2010; Ward et al., 2015). 
Studies have shown the mechanism of how DCIS turns into invasive breast 
cancer (Hu et al., 2008). However, early molecular alterations preceding DCIS 
have not been clearly demonstrated so far (Rivenbark et al., 2013). 
 
Breast cancers are classified by immunohistochemistry to detect the expression 
of certain protein biomarkers, including estrogen receptor (ER), progesterone 
receptor (PR), and human epidermal growth receptor 2 (HER2) and various 
cytokeratins. Based on this clinical classification, breast cancer can be classified 
as ER+/PR+HER2-, ER+/PR+/HER2+, ER-/PR-/HER2+, and ER-/PR-/HER2- breast 
cancers. Breast cancer can also be classified by gene expression (Perou et al., 
2000; Sorlie et al., 2003; Sorlie, 2004) . Based on this molecular classification, 
breast cancer can be classified as six molecular subtypes, luminal A (ER+), 
luminal B (ER+/HER2+), HER2+, basal-like, claudin-low, and normal-like breast 
cancers (Rakha et al., 2008; Rivenbark et al., 2013).  
 
ER+ and HER2+ breast cancers can be treated by effective targeted therapy of 
anti-estrogen treatment (tamoxifen) or anti-HER2 drug (trastuzumab), 
respectively, both in conjunction with chemotherapy (Mukai, 2010; Rimawi et al., 
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2015). These targeted treatments have improved survival and the long-term 
outcomes for ER+ and HER2+ patients dramatically. However, basal-like and 
claudin-low molecular subtypes of breast tumors lack the expression of ER, PR 
as well as amplification of HER2 (ER-PR-HER2-), and are therefore also referred 
to as triple-negative breast cancers (TNBCs). TNBCs tend to be more aggressive 
compared to ER+ breast cancers, and there are no effective targeted therapies 
(Chacón and Costanzo, 2010; Dent et al., 2007; Li et al., 2013). Though they 
respond to some chemotherapies, the patients often have poor recurrence-free 
and overall survival outcomes (Kassam et al., 2009; Kennecke et al., 2010; 
Liedtke et al., 2008). 
 
Tumor Heterogeneity and Cancer Stem Cells 
A single tumor harbors a mixture of different subpopulations with distinct 
molecular properties (Meacham and Morrison, 2013; Skibinski and Kuperwasser, 
2015). Two models are used to explain this intratumor heterogeneity, the clonal 
evolution model and the cancer stem cell model, which are not mutually 
exclusive but could also be integrated together (Campbell and Polyak, 2014; 
Kreso and Dick, 2014).  
 
The clonal evolution model states that tumor cells acquire various mutations over 
time and cancer could initiate in any random single cell. Certain mutation could 
give cells growth advantage over other normal cells, and these cells will become 
					4	
more aggressive and may leave a large number of offspring by chance. Thus, 
during tumor progression, any cell within the tumor could potentially be the one 
that drives tumor progression and results in therapy resistance and recurrence 
since mutations will occur in random cells over time. 
 
The cancer stem cell model states that there is a small subpopulation of cells in 
the tumor that have stem cell-like properties, called cancer stem cells (CSCs). 
CSCs have the ability of self-renewal and can also differentiate into different cell 
types. They are thought to be responsible for cancer recurrence. Current 
therapies kill tumor cells but not CSCs, and CSCs can proliferate extensively. 
Thus, despite good therapeutic response by the bulk tumor, it shrinks but will 
grow back. Moreover, the recurred tumor will gain resistance to the previous 
therapies. 
 
In this work, I focused on the CSC model. TNBCs harbor a relatively high 
frequency of CSCs compared with other breast cancer subtypes. This could be 
one of the reasons why TNBCs are more aggressive with poor recurrence-free 
and overall survival outcomes. Despite the evidence supporting the existence of 
CSCs, much less is known about the origin of these cells and the mechanisms 
that regulate their functions.  
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CSCs can be isolated by cell-surface markers, and a series of assays can be 
conducted to examine their stem-cell properties. The gold standard measure of 
CSCs is examining their ability to repopulate new tumors and maintain the long-
term clonal growth by either transplantation into serial recipients or in situ 
tracking. Initial studies on CSCs were conducted in acute myeloid leukemia 
(AML), and the CD34+CD38- subpopulation was identified as leukemia-initiating 
cells (Bonnet and Dick, 1997; Lapidot et al., 1994). After that many studies on 
CSCs in various solid tumors followed (Collins et al., 2005; Eramo et al., 2008; 
Hermann et al., 2007; Li et al., 2007; O'Brien et al., 2007; Patrawala et al., 2006; 
Prince et al., 2007; Ricci-Vitiani et al., 2007; Singh et al., 2004; Wu et al., 2007). 
The first identification of CSCs in a solid tumor was in human breast cancer (Al-
Hajj et al., 2003). A CD24-CD44+ subpopulation was identified as CSCs in breast 
cancer by showing this subpopulation alone is sufficient to generate new tumors 
in immune-deficient mice while the other three subpopulations (CD24+CD44+, 
CD24-CD44-, and CD24+CD44-) cannot (Al-Hajj et al., 2003).  
 
Integrins  
In this context, we are interested in integrins in breast cancer. Integrins are 
transmembrane receptors that form heterodimers composed of α and β subunits. 
In mammals, the integrin family comprises 18 α and 8 β subunits that bind 
noncovalently, generating 24 unique integrins, and they bind to specific ligands 
including collagen, fibronectin, vitronectin and laminin (Hynes, 2002). Integrin 
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subunits span the cell membrane with a large extracellular domain, a single 
transmembrane domain and a short cytoplasmic tail of 40-70 amino acids. The 
exception is the β4 subunit, which has a cytoplasmic domain of 1088 amino 
acids, one of the largest known cytoplasmic domains of any membrane protein 
(Campbell and Humphries, 2011; Srichai and Zent, 2010; Takada et al., 2007).  
 
As adhesion receptors, integrins mediate cell-cell adhesions as well as cell 
adhesion to extracellular matrix proteins. All integrins except integrin α6β4 are 
connected to actin, while the integrin β4 subunit connects to keratin intermediate 
filaments. They can form adhesion structures such as focal adhesion and 
hemidesmosome which connect ligands in the ECM with the cytoskeleton. Other 
than functioning as adhesion receptors, integrins also mediate signaling 
transduction and play important roles in cell proliferation, division, apoptosis, 
survival, motility, and differentiation (Guo and Giancotti, 2004; Levental et al., 
2009; Glukhova and Streuli, 2013). Each integrin plays distinct, nonredundant 
roles shown by the phenotypes of genetic knockout mice, such as in 
development, vasculogenesis and immune responses (Takada et al., 2007). 
 
Unlike other transmembrane receptors, integrins mediate signaling in a 
bidirectional way (Hynes, 2002). They connect the extracellular and intracellular 
environments by binding ligands in the ECM and adaptor molecules in the 
cytoplasm through outside-in signaling or inside-out signaling. Outside-in 
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signaling involves the extracellular domain of integrins binding to their ligands to 
promote conformational changes first, which is followed by integrin clustering and 
the assembly of large intracellular adhesion complexes. Inside-out signaling 
involves an internal signaling molecule binding to the cytoplasmic tail of integrins 
first, which then induces conformational changes and influences the binding of 
integrins to their ligands. Moreover, integrins also participate in signaling 
crosstalk, where in addition to the activation of their own downstream signaling 
cascades, they interact with and regulate the activation of growth hormones and 
G-protein coupled receptor-induced signaling pathways (Mariotti et al., 2001; 
Trusolino et al., 2001; Guo et al., 2006).  
 
Integrin α6β4 in Epithelial Biology 
Integrin α6β4 is referred to as β4 integrin since its only partner is the α6 subunit. 
Integrin β4 is special among all integrin subunits in that it has an extremely large 
cytoplasmic domain and it connects to keratin intermediate filaments instead of 
the actin cytoskeleton (Borradori and Sonnenberg, 1999; Dowling et al., 1996; 
Green and Jones, 1996). It is expressed primarily on the basal surface of most 
epithelia and in a few other cell types, preferentially binding to most of the known 
laminins (Lee and Streuli, 2014; Mercurio, 1995). In normal cells, β4 integrin is 
essential for the organization and maintenance of epithelial architecture by 
serving as an important component of the stable and rigid adhesive structures 
termed hemidesmosomes (HDs) that link the intermediate filament cytoskeleton 
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with laminins in the basement membrane (BM) (Borradori and Sonnenberg, 
1999; Dowling et al., 1996; Green and Jones, 1996).  
 
Homozygous knockout reveals the function of β4 in maintaining the integrity of 
epithelia, especially the epidermis. In the absence of β4 expression, the 
epidermis detaches from the dermis in response to mechanical stress, which 
leads to death of β4 knockout mice shortly after birth (Dowling et al., 1996; van 
der Neut et al., 1996; 1999a). This critical role for β4 derives from its ability to 
mediate the formation of HD on the basal cell surface (Borradori and 
Sonnenberg, 1999; Green and Jones, 1996). HDs are most pronounced in 
stratified epithelia, but rudimentary forms exist in most epithelia (Green and 
Jones, 1996).  
 
Although many studies have been conducted on the contribution of β4 to 
epithelial biology in the past two decades, its role in mammary gland 
development is unclear and confusing (Klinowska et al., 2001). During 
embryogenesis, integrin β4 is expressed at least from embryonic day 12.5 
(E12.5), restricted in the mammary epithelial bud which begins to elongate to 
form the rudimentary mammary tree after E14.5. The adult mammary glands are 
composed of two layers of cells: luminal cells and myoepithelial cells. Integrin β4 
is expressed primarily in myoepithelial cells and anchors them to the basement 
memberane (Gjorevski and Nelson, 2011). Seminal studies by Bissell and others 
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using three-dimensional cultures revealed the importance of laminins in 
mammary morphogenesis and the contribution of the α6 integrins (α6β4 and 
α6β1) to this process (Nisticò et al., 2014). Our previous work shows that integrin 
β4 regulation of parathyroid hormone related protein (PTHrP) contributes to the 
ability of this integrin to regulate mammary bud development during 
embryogenesis (Li et al., 2015).  
 
Rational for the Thesis Work 
In breast cancer, β4 has been shown to be important for tumor formation, 
invasion and metastasis (Soung et al., 2011). The role of β4 in tumor migration 
and invasion has been extensively studied. In cancer cells, β4 integrin switches 
from associating with HD to interacting with actin cytoskeleton and redistributes 
to cell protrusions, which can stimulate carcinoma migration and invasion 
(Lipscomb and Mercurio, 2005; Rabinovitz and Mercurio, 1997; Rabinovitz et al., 
1999). Integrin β4 also promotes tumor invasion by regulating several 
downstream effector molecules and activating various signaling pathways. 
Integrin β4, together with growth factor receptors, initiates signaling cascades 
involving Shp2 and Src, which leads to activation of PI3K and Ras pathways 
(Shaw et al., 1997; Mercurio, 2003; Bertotti et al., 2006). As a result, integrin β4 
enhances expression of cancer related genes such as VEGF, ERBB3, NFAT, 
NF-kB, STAT3 and c-Jun at the translational or transcriptional levels (Chung et 
					10	
al., 2002; Folgiero et al., 2007; Gerson et al., 2012a; Jauliac et al., 2002; Yoon et 
al., 2006; Zahir et al., 2003).  
 
Integrin β4 has also been found to be essential for breast tumor formation. Our 
lab showed that β4 is important for breast tumor growth by demonstrating that 
SUM-159 breast cancer cells with β4 knocked down generate fewer and smaller 
tumors in vivo compared to control cells (Lipscomb et al., 2005). Moreover, this 
tumor growth phenotype could be rescued by overexpressing β4 back into the 
knockdown cells. Another study also shows that β4 promotes tumor formation by 
amplifying ERBB2 signaling (Guo et al., 2006). However, the mechanism of how 
integrin β4 regulates tumor formation still needs to be further investigated.  
 
The role of CSCs in tumor formation has arisen much interest in the field 
studying tumor initiation. Several integrins such as α6 and β1 have been shown 
to be stem cell markers (Pontier and Muller, 2009). However, less is known about 
the role of β4 in CSCs. Data in our lab suggests that β4 may be involved in stem 
cell properties by showing that β4 knockout mammary buds cannot develop into 
mature mammary glands when transplanted into immune-deficient mice (Li et al., 
2015). Moreover, several studies suggest that β4 is involved in CSCs of breast 
cancer and lung cancer in the past two years (Zheng et al., 2013; Vieira et al., 
2014). In non-small-cell lung cancer, integrin β4 has been identified as a CSC 
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marker by showing that a rare population of CD24+ITGB4+Notchhi cells are able 
to form new tumors in serial transplantation assay (Zheng et al., 2013). Another 
study shows that P-cadherin signaling induces stem cell properties in basal-like 
breast cancer cells through integrin β4 (Vieira et al., 2014). This study 
demonstrates that P-cadherin directly interacts with β4 and regulates the 
expression of both integrin α6 and β4 subunits, which are essential for stem cell 
properties shown by mammosphere assay (Vieira et al., 2014). However, the 
mechanism of β4 regulation on CSCs is still unclear. Given these data and the 
importance of CSCs in tumor initiation, I was interested in investigating the role of 



















Integrin β4 is not only very important for the organization and maintenance of 
epithelial architecture in normal epithelia, but it also plays essential roles in 
cancer. It has been shown to be important for tumor formation, invasion and 
metastasis. However, the mechanism of how integrin β4 is involved in tumor 
formation is still unclear. My study shows that integrin β4 is heterogeneously 
expressed in breast cancer and the β4+ population is critical for tumor formation. 
It further shows that β4 affects CSCs in a non-cell-autonomous manner and I 




Integrin β4 has been shown to be important for tumor formation and survival in 
breast cancer (Guo et al., 2006; Lipscomb et al., 2005). However, the 
mechanism involved is still not very clear. Breast CSCs were identified as CD24-
CD44+ by showing that it is necessary and sufficient to form new tumors in vivo 
while other three subpopulations (CD24-CD44-, CD24+CD44-, CD24+CD44+) 
cannot (Al-Hajj et al., 2003). Our lab showed that β4 is important for mammary 
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gland development during embryogenesis through regulating parathyroid 
hormone-related protein (PTHrP) expression (Li et al., 2015). In this study, we 
knocked out integrin β4 using MMTV-Cre and found that the mammary bud 
elongation was blocked, which is very similar to the phenotype of PTHrP 
knockout mice. Upon further investigation, we found that PTHrP expression was 
decreased in β4 knockout mammary bud, and the mammary bud elongation 
phenotype could be rescued by adding additional PTHrP when β4 knockout 
mammary bud was cultured in vitro. Moreover, in the study, the fact that β4 
knockout mammary buds cannot develop into mature mammary glands when 
transplanted into immune-deficient mice suggests that β4 could be potentially 
involved in stem cell properties. Compared to integrin α6 and β1, not much is 
known about β4 in mammary stem cells (Pontier and Muller, 2009). Integrin β4 
has been indicated in progenitor cells (Chapman et al., 2011; Yoshioka et al., 
2013). Moreover, β4 is identified as a marker for CSCs in non-small-cell lung 
cancer (Zheng et al., 2013). In breast cancer, a study has shown that P-cadherin 
regulates CSC functions through integrin β4 (Vieira et al., 2012; 2014). Given all 
these studies and that CSCs are important for tumor formation, I wanted to 
investigate whether integrin β4 is involved in CSC functions and the mechanisms 
involved. 
 
Previously, tumor formation is believed to be associated with epithelial-to-
mesenchymal transition (EMT) (Thiery et al., 2009). It has been shown that EMT 
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generates cells with properties of stem cells, and CSCs express mesenchymal 
markers with decreased epithelial markers (Mani et al., 2008). However, integrin 
β4 is a gene associated with epithelial cells, and our lab showed that β4 is 
downregulated dramatically during EMT induced by TGF-β or Snail (Chang et al., 
2013; Yang et al., 2009). In another system that our lab has been using, we 
sorted out two populations from Src-transformed MCF10A cells based on α6 
staining (Goel et al., 2014). α6hi population has epithelial traits while α6lo 
population is mesenchymal based on both cell morphology and molecular 
markers (Goel et al., 2014). Moreover, α6lo population has higher CSC properties 
but lower β4 expression compared to α6hi population. Based on these 
observations, it seems that β4 expression is not directly expressed by CSCs. 
Since β4 is important for tumor formation while it is not expressed in CSCs, I 
propose that β4 is expressed heterogeneously in breast tumors and this β4+ non-
CSC subpopulation is important for tumor formation.   
 
Results and Discussion 
2.1 Integrin β4 is expressed heterogeneously in breast tumors. 
We have a patient-derived xenograft (PDX) model in our lab. I used PDX tumors 
derived from two TNBC patients labeled as  #1126 and #1258, respectively (Fig 
1A). β4 expression was first examined in these two tumor samples by 
immunofluorescence (IF) staining (Fig 1B). The result shows that β4 is expressed 
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heterogeneously by a subpopulation of cells in the tumor. To examine the 
molecular difference between β4+ and β4- populations, I sorted out β4+ and β4- 
cells by FACS in PDX tumor #1126 (Fig 1C).  
 
qPCR data shows that the β4+ subpopulation expresses a lower level of CSC 
marker OCT4 compared to β4- subpopulation (Fig 1D), which confirms that β4 is 
not directly expressed by CSCs. Since our lab showed that β4 is associated with 
basal-like breast cancer (Lu et al., 2008) and it is downregulated during EMT 
together with epithelial markers (Chang et al., 2013; Yang et al., 2009), I checked 
the expression of several basal and epithelial markers.The β4+ subpopulation 
expresses higher levels of basal and epithelial genes compared to the β4- 
subpopulation (Fig 1D). 
 
The Ewald group showed that cell dissemination during invasion needs an 
epithelial program (Shamir et al., 2014). Moreover, a basal epithelial population is 
shown as leader cells at the invading front in breast cancer (Cheung et al., 2013). 
These studies indicate that not all cells undergo EMT during tumor progression, 
and there is a basal epithelial population driving tumor invasion. Interestingly, two 
back-to-back papers recently showed that EMT is not required for metastasis and 
epithelial cells can intravasate into the blood system and form metastasis 
(Cheung et al., 2013; Fischer et al., 2015; Shamir et al., 2014; Zheng et al., 
2015). These results contradict with the previous model that cells need to 
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undergo EMT and become mesenchymal-like to break away from the primary 
site (Thiery et al., 2009). Overall, these studies address the important role of a 
basal-epithelial population within the tumor during tumor progression other than 
the cells that undergo EMT which are previously believed to drive tumor 
progression. 
 
In cancer, integrin β4 switches from associating with HD to connecting with actin 
and redistributing to cell protrusions (Lipscomb and Mercurio, 2005; Rabinovitz 
and Mercurio, 1997; Rabinovitz et al., 1999). Moreover, the invading front of 
several carcinomas are enriched in the expression of β4 and its ligand laminin-
332 (Kim et al., 2011a; Pyke et al., 1995; Xue et al., 2011). β4 has been shown 
to drive tumor invasion by regulating several downstream effector molecules and 
signaling pathways (Gerson et al., 2012; Shaw et al., 1997). My data also shows 
that the β4+ population is associated with a basal epithelial program (Fig 1D). 
Based on all these findings, I propose that β4+ population may be the leader cells 
during invasion that Ewald group reported in their studies (Cheung et al., 2013; 
Shamir et al., 2014). To examine whether the β4+ population is present at the 
invasive front to drive tumor invasion and to track β4 expression during tumor 
progression and metastasis, I made a β4 reporter mouse using CRISPR (see 
Chapter III). In this work, I’m interested in investigating whether the β4+ 
subpopulation is important for tumor formation and the mechanism involved other 
than their potential role in tumor invasion.  
					17	
 
2.2 Integrin β4 regulates CSCs in a non-cell-autonomous manner through PTHrP   
      paracrine signaling 
I checked some genes that are important for CSC functions, and I found an 
interesting gene expression pattern that β4- and β4+ cells have in certain 
important paracrine signaling pathways for example, the notch signaling pathway. 
qPCR data show that β4+ cells express higher level of JAG1 while β4- cells 
express higher NOTCH3 as well as HEY1, which is a downstream target in Notch 
signaling (Fig 1D). Notch signaling is established to be important for CSC self-
renewal (Bouras et al., 2008; Dontu et al., 2004; Harrison et al., 2010). One study 
showed that NF-kB regulates CSCs in a non-cell-autonomous manner through 
Notch paracrine signaling. CSCs express notch3 receptors, and NF-kB regulates 
JAG1 expression in non-CSCs (Yamamoto et al., 2013). This non-cell-
autonomous regulation model is very similar with what my results indicate. Thus, 
I proposed that β4+ non-CSCs can interact with β4- CSCs through paracrine 
signaling. 
 
To show that β4+ and β4- populations can interact with each other, I explored the 
Src-transformed MCF10A system in our lab where β4hi and β4lo populations were 
isolated (Goel et al., 2014). It has been shown that the β4lo population has CSC 
properties compared to the β4hi population (Goel et al., 2014). Part of the results 
from RNA-seq on β4hi and β4lo populations is shown in Table 1. I labeled β4hi 
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population with GFP and β4lo population with mCherry. I mixed them together 
and plated them in single cells on Matrigel. The result shows that they grow into 
cell clusters together in 3D culture (Fig 2A). This indicates that β4hi and β4lo 
populations can interact with each other and grow together in 3D culture. 
 
Our lab showed that integrin β4 regulates PTHrP expression during embryonic 
mammary gland development and there are many signaling pathways during 
embryogenesis that have parallel signaling pathways in cancer, I checked the 
expression of PTHrP and its receptor PTH1R in β4+ and β4- populations sorted 
from PDX tumors (Li et al., 2015). β4+ cells express higher PTHrP while β4- cells 
express higher PTHrP as well as BMP4 which is a downstream target of PTH1R 
signaling (Fig 1D). It is known that PTHrP is expressed primarily by epithelial-
derived cells, and its receptor PTH1R expression is restricted to mesechymal 
cells. Thus PTH1R signaling is activated in the paracrine manner. PTHrP 
promotes increased tumor cell growth in breast cancer lines as well as in vivo 
(Dittmer et al., 2006). PTHrP also drives breast tumor progression and 
metastasis examined by mouse model (Li et al., 2011). However, no one has 
shown that PTHrP is involved in CSCs functions.  
 
To better characterize β4+ and β4- population within a breast tumor, RNA-seq 
was performed on β4+ and β4- populations sorted from PDX tumor #1258 (Fig 
1E). Part of the results was shown in Table 2. I first used mouse lineage markers 
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CD31, CD45 and Ter-119 to exclude the potential mouse stromal cells recruited 
to the PDX tumor, and then sorted out the β4+ and β4- cells in Lin- cells. I 
confirmed β4 expression in β4+ and β4- subpopulations before sending them for 
RNA-seq (Fig 1E). RNA-seq data is similar with the previous qPCR data in that 
β4+ population expresses lower level of CSC markers while is associated with a 
basal epithelial program (Table 2).  
 
PTHrP expression is always associated with β4. I checked this association in 
another two systems. In the Src-transformed MCF10A system, PTHrP is 
associated with β4hi population (Table 1). I overexpressed VEGF promoter with 
GFP tag in MDA-MB-231 cells and sorted out GFP+ cells which have higher 
VEGF activity (VEGF-high). Our lab has shown that VEGF-high cells have CSC 
properties (Goel et al., 2014). I checked β4 and PTHrP expression in VEGF-low 
and VEGF-high cells by qPCR, and found that PTHrP expression is associated 
with β4 in VEGF-low population (Fig 2B). I knocked down β4 with siRNA in 
MCF10A cells, and found that PTHrP expression decreased at both mRNA and 
protein level (Fig 2C). When I ligated integrin α6β4 by plating the cells on 
laminins, PTHrP expression increase (Fig 2D). This indicates that PTHrP 
expression is directly induced by ligation of integrin α6β4. Based on these results, 
I propose that β4+ non-CSCs and β4- CSCs interact with each other through 
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paracrine signaling, which potentially involves β4 regulation on PTHrP 
expression.  
 
2.3 Integrin β4 is essential for CSC functions. 
Our lab has shown that β4 integrin is important for mammary tumor formation 
and growth by knocking down β4 using shRNA in SUM-159 cells (Lipscomb et 
al., 2005). The shβ4 cells form fewer and smaller tumors when injected into the 
mammary fat pad of immunocompromised mice compared to shGFP cells. 
Overexpressing β4 back in to the shβ4 cells can rescue the tumor formation 
phenotype. To investigate the mechanism involved, I studied the same system by 
knocking down β4 in SUM-159 cells using shRNAs (Fig 3A). Since CSCs are 
known to be very important for tumor formation, I first examined if the tumor 
formation phenotype we got after β4 knocking down was due to decrease in the 
amount of CSC population. Interestingly, I found that knocking down β4 doesn’t 
decrease the CD24-CD44+ population which is identified as CSCs in breast 
cancer (Al-Hajj et al., 2003), but it dramatically reduces CD24+CD44+ population 
(Fig 3B).  
 
To further investigate the mechanism, I sorted out CD24-CD44+ and 
CD24+CD44+ populations in SUM-159 cells, and checked gene expression in 
these two populations by qPCR. The data show that CD24-CD44+ CSCs express 
lower levels of integrin β4 but higher PTH1R. The CD24+CD44+ population 
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expresses higher level of basal and epithelial markers as well as PTHrP (Fig 3C). 
I cultured these two populations separately for 1 week and checked CD24 and 
CD44 expression by FACS again. The CD24-CD44+ population can give rise to 
the cell profiles in the parental SUM-159 cells, both CD24-CD44+ and 
CD24+CD44+ populations (Fig 3D). However, CD24+CD44+ population can only 
give rise to itself (Fig 3D). As one major property of stem cells, they should be 
able to differentiate into different types of cells. This result confirms that CD24-
CD44+ population is CSCs while CD24+CD44+ population doesn’t have this stem 
cell property. Moreover, this result also indicates that integrin β4 is essential for 
CSC functions. As it is discussed above, I expected that intact CSC population 
(CD24-CD44+) in SUM-159 cells should be able to differentiate into all cell 
subtypes in SUM-159 cells, just as shown in Fig 3D. However, after knocking 
down β4, there was a dramatic reduce in CD24+CD44+ population (Fig 3B), 
which means that CD24-CD44+ cells in shβ4 cells failed to give rise to 
CD24+CD44+ population in the parental SUM-159 cells. This indicates that CSC 
function of CD24-CD44+ population is defective without β4. Thus, I proposed that 
integrin β4, though it is not directly expressed by CSCs, is essential for 
maintaining CSC functions. 
 
Since shRNAs don’t fully knock down β4, I used CRISPR to target β4 in MDA-
MB-231 cells. I sorted out single cells and grew them into colonies before 
selecting the clones with β4 completely knocked out. I selected one single cell 
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clone from each of the two guide RNAs sg3 and sg4, and performed RNA-seq 
(Fig 3E). β4 expression was examined in control and two knockout clones before 
RNA-seq (Fig 3F). Part of the RNA-seq results is shown in Table 3. 
 
2.4 Integrin β4 is associated with CD24+CD44+ population in breast tumor.  
I checked β4 expression by FACS in a Luminal A type human breast tumor. 
There are β4-low and β4-high populations, and β4-low cells are mostly CD24-
CD44+ while β4-high cells are mostly CD24+CD44+ (Fig 4A). If the tumor cells are 
analyzed first by CD24 and CD44 expression, there are two subpopulations 
CD24-CD44+ and CD24+CD44+ (Fig 4A). Interestingly, CD24+CD44+ 
subpopulation has higher level of β4 expression compared to CD24-CD44+ 
subpopulation.  
 
The model I propose from my data is described in fig 4B. β4 is expressed 
heterogeneously in breast tumor with β4+ and β4- populations. The β4+ 
population is CD24+CD44+ expressing basal and epithelial markers, and the β4- 
population is CD24-CD44+ with CSC properties. β4+ non-CSCs are important for 
and interact with β4- CSCs by providing the ligands for paracrine signaling. 
Together, β4 regulates CSC functions in a non-cell-autonomous manner, and 
both β4+ and β4- populations are needed for tumor formation.  
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Materials and Methods 
Antibodies. β4 (505, for western blot) (Rabinovitz et al., 1999); β4 (4399B, for 
FACS, IF and IHC); actin (Sigma-Aldrich); phycoerythrin-conjugated anti-CD44 
(BD Bioscience); Alexa Fluor 647 anti-CD24 (BD Bioscience); PTHrP (a gift from 
Dr. Jiarong Li). 
 
Cell lines. SUM-159 cells were provided by Dr. Steve Ethier (Medical College of 
South Carolina). MCF10A cells were obtained from the Barbara Ann Karmanos 
Cancer Institute. MDA-MB-231 cells were purchased from American Type 
Culture Collection. ER-Src-transformed MCF10A cells were provided by Dr. 
Kevin Struhl (Harvard Medical School). Isolation of the CD24-CD44+ population 
from these Src-transformed MCF10A cells and characterization of the α6hi and 
α6lo populations have been described (Goel et al., 2014). The SUM-159 shGFP 
and β4-shRNAs (sh68 and sh70) human breast carcinoma cell lines were 
generated and maintained as described previously (Chung et al., 2004). MDA-
MB-231 cells stably expressing GFP under control of the VEGF promoter were 
generated and maintained as described previously (Goel et al., 2014). MCF10A 
siCtril and siβ4 cells were generated as described previously (Gerson et al., 
2012b). A6hi and a6low cells stably expressing GFP and mCherry, respectively 
were generated by PCDH-GFP and PLV-mCherry (Addgene) lentiviral plasmids 
and selected on puromycin. MDA-MB-231 cells stably expressing sgRNAs were 
generated by cloning indicated sgRNA sequences into v2 lentiviral backbone 
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plasmid (Addgene). Single-cell sorting was performed to select clones with β4 
knockout.  
 
RNA-seq. RNA was extracted from the indicated cells and sent to Applied 
Biological Materials (ABM) for quantification and sequencing. Sequencing was 
performed on the paired ends of the mRNA fragment with a reading length of 
75bps. Each sample had a sequencing depth of 8 million.  
 
Cell-Based Assays. Flow cytometry was used to analyze surface expression of 
the β4 integrin, CD44, CD24 and lineage markers (CD31, CD45, Ter-119) in 
breast cancer cell lines and breast tumors. Cells in culture were detached, 
stained with antibodies and analyzed by FACS. PDX tumors and primary human 
breast tumors were dissociated into single cell suspensions as described before 
staining and FACS analysis (Goel et al., 2013). For 3D co-culture, α6hi-GFP and 
α6lo-mCherry cells were suspended in single cells and plated on Matrigel-coated 
plates for 1 week. For integrin α6β4 ligation assay, MCF10A cells were cultured 
on FN, LM111 and LM511-coated plates for 4 hours before collecting for RNA 
isolation. 
 
Tumor samples. For PDX tumors, triple-negative breast tumor tissue samples 
#1126 and #1258 were obtained from breast cancer surgery patients, through 
Brigham and Women’s Hospital and Massachusetts General Hospital. These 
					25	
breast tumor samples were cut into small pieces, which were then surgically 
implanted into the fourth mammary fat pad of NSG mice. Tumor xenografts were 
expanded into multiple recipient NSG mice for several passages. For primary 
human tumors, two Luminal A type breast tumors were obtained from Tissue 
Bank at UMass Medical School. 
 
Immunoblotting and qPCR. Cells were extracted in RIPA (50mM Tris-HCL [pH 
7.4], 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1mM PMSF, and 
protease inhibitors). The proteins were separated by SDS-PAGE and 
immunoblotted using Abs as specified in the figure legends. For qPCR, RNA 
isolation was done with the NucleopSpin RNA kit (Macherey-Nagel) and 1ug of 
total RNA was used to produce cDNAs using Roche First strand synthesis kit 
(Roche). qPCR was performed using a SYBR green (Applied Biosystems) 
master mix as described by the manufacturer. Sequences for qPCR primers 















Figure 3. Knocking down integrin β4 affects CSC functions. 
(A) Integrin β4 was knocked down in SUM-159 cells by two shRNAs, sh68 and 
sh70. (B) CD24+CD44+ population was reduced dramatically after β4 was 
knocked down. (C) CD24-CD44+ and CD24+CD44+ populations in SUM-159 cells 
were sorted, and the expression of indicated genes were examined by qPCR. (D) 
CD24-CD44+ and CD24+CD44+ populations were cultured separately for 1 week 
before CD24 and CD44 expression were analyzed by FACS again. (E) MDA-MB-
231 cells stably expressing sgRNAs (sg3 and sg4) targeting integrin β4 were 
generated. Three clones derived from single cells for each sgRNA were selected,  
and β4 expression was examined by western blot. (F) Expression of integrin β4 is 













Table 2. Summary of RNA-seq of β4+ and β4- populations in PDX tumor  
Top 100 genes in β4+ population 
Rank gene_id 
fold.change. 
β4- / β4+ genename 
1 ERP27 0.055810447 endoplasmic reticulum protein 27 
2 EDN2 0.068085924 endothelin 2 
3 GABRP 0.07806187 gamma-aminobutyric acid (GABA) A receptor, pi 
4 ITGB4 0.078433946 integrin, beta 4 
5 SCGB2A2 0.08094378 secretoglobin, family 2A, member 2 
6 PROM2 0.081264473 prominin 2 
7 SOSTDC1 0.086105138 sclerostin domain containing 1 
8 KRTAP19-5 0.088997743 keratin associated protein 19-5 
9 LINC00617 0.089003394  
10 CAPS 0.090619562 calcyphosine 
11 
EEF1E1-
MUTED 0.091320952  
12 ITGB6 0.100665881 integrin, beta 6 
13 DEFB109P1 0.105029219 defensin, beta 109, pseudogene 1 
14 KRTAP5-2 0.105787866 keratin associated protein 5-2 
15 SLC34A2 0.108548112 
solute carrier family 34 (type II sodium/phosphate 
cotransporter), member 2 
16 SNORA58 0.10884567 small nucleolar RNA, H/ACA box 58 
17 CLDN8 0.111889128 claudin 8 
18 MIR205HG 0.112553915 MIR205 host gene 
19 ZNF20 0.114010716 zinc finger protein 20 
20 S100A14 0.114327068 S100 calcium binding protein A14 
21 EPHA1 0.115049589 EPH receptor A1 
22 AZGP1 0.115545491 alpha-2-glycoprotein 1, zinc-binding 
23 EPN3 0.116073033 epsin 3 
24 PROM1 0.116701246 prominin 1 
25 SCARNA10 0.119531437 small Cajal body-specific RNA 10 
26 PRODH 0.121185626 proline dehydrogenase (oxidase) 1 
27 FXYD3 0.121581886 FXYD domain containing ion transport regulator 3 
28 KRT17 0.125540397 keratin 17, type I 
29 KRTAP21-2 0.127566641 keratin associated protein 21-2 
30 HIST1H2AB 0.128848047 histone cluster 1, H2ab 
31 S100P 0.132093822 S100 calcium binding protein P 
32 VIPR1 0.132249714 vasoactive intestinal peptide receptor 1 
33 LOC93432 0.138217499 maltase-glucoamylase (alpha-glucosidase) 
34 EFNA3 0.139139826 ephrin-A3 
35 DEFB109P1B 0.141477134 defensin, beta 109, pseudogene 1B 
36 LOC642423 0.142028508 golgin A2 pseudogene 
37 TRIM29 0.142518236 tripartite motif containing 29 
38 LCN2 0.142842554 lipocalin 2 
39 TMPRSS13 0.142981928 transmembrane protease, serine 13 
40 KRTCAP3 0.143176989 keratinocyte associated protein 3 
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41 MB 0.145079255 myoglobin 
42 NAALADL2 0.147429106 N-acetylated alpha-linked acidic dipeptidase-like 2 
43 INHBB 0.147610419 inhibin, beta B 
44 BSPRY 0.1478731 B-box and SPRY domain containing 
45 LIPG 0.149503414 lipase, endothelial 
46 AQP3 0.151534351 aquaporin 3 (Gill blood group) 
47 RASAL1 0.152332362 RAS protein activator like 1 (GAP1 like) 
48 CAMSAP3 0.152843564 
calmodulin regulated spectrin-associated protein 
family, member 3 
49 EHF 0.153213829 ets homologous factor 
50 LAD1 0.153312724 ladinin 1 
51 KRT14 0.153942955 keratin 14, type I 
52 LGALS7 0.15404238 lectin, galactoside-binding, soluble, 7 
53 PADI2 0.156071582 peptidyl arginine deiminase, type II 
54 SUSD4 0.156225299 sushi domain containing 4 
55 UNC13D 0.156339417 unc-13 homolog D (C. elegans) 
56 LOC100128338 0.156403451  
57 SLPI 0.1564616 secretory leukocyte peptidase inhibitor 
58 VGLL1 0.158340308 vestigial-like family member 1 
59 GUCY1B3 0.158370436 guanylate cyclase 1, soluble, beta 3 
60 VTCN1 0.158429337 V-set domain containing T cell activation inhibitor 1 
61 KRT15 0.160475562 keratin 15, type I 
62 DLX3 0.16236596 distal-less homeobox 3 
63 
JMJD7-
PLA2G4B 0.163768749 JMJD7-PLA2G4B readthrough 
64 TMEM54 0.166422176 transmembrane protein 54 
65 ESRP1 0.167872286 epithelial splicing regulatory protein 1 
66 B4GALNT3 0.167928138 beta-1,4-N-acetyl-galactosaminyl transferase 3 
67 EFCAB4A 0.167970125  
68 PVRL4 0.168173739 poliovirus receptor-related 4 
69 FMOD 0.169938592 fibromodulin 
70 MUC5B 0.170962449 mucin 5B, oligomeric mucus/gel-forming 
71 AGR2 0.171148032 anterior gradient 2 
72 ATP2C2 0.172121778 ATPase, Ca++ transporting, type 2C, member 2 
73 CALB2 0.172161605 calbindin 2 
74 IGFL1 0.172251795 IGF-like family member 1 
75 MUC1 0.172274959 mucin 1, cell surface associated 
76 IGFL2 0.174560115 IGF-like family member 2 
77 PTPRU 0.174636105 protein tyrosine phosphatase, receptor type, U 
78 FLVCR2 0.175418597 
feline leukemia virus subgroup C cellular receptor 
family, member 2 
79 RTN4RL1 0.176413331 reticulon 4 receptor-like 1 
80 LOC728463 0.178605874  
81 RBP1 0.178629336 retinol binding protein 1, cellular 
82 DSC3 0.179223577 desmocollin 3 
83 KRT6B 0.179990217 keratin 6B, type II 
84 FREM2 0.180121264 FRAS1 related extracellular matrix protein 2 
85 KRT6C 0.180811098 keratin 6C, type II 
86 SPINT1 0.180864618 serine peptidase inhibitor, Kunitz type 1 
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87 HIST1H4D 0.181680765 histone cluster 1, H4d 
88 TMC6 0.181806274 transmembrane channel-like 6 
89 C6orf15 0.183153963 chromosome 6 open reading frame 15 
90 PDGFA 0.183711689 platelet-derived growth factor alpha polypeptide 
91 ALDH3B2 0.184243618 aldehyde dehydrogenase 3 family, member B2 
92 MAP7 0.184346294 microtubule-associated protein 7 
93 CLDN23 0.18458237 claudin 23 
94 NEBL 0.187068659 nebulette 
95 TNNI2 0.187391417 troponin I type 2 (skeletal, fast) 
96 HSD11B2 0.188092237 hydroxysteroid (11-beta) dehydrogenase 2 
97 CLIC3 0.188237351 chloride intracellular channel 3 
98 S100A16 0.189391975 S100 calcium binding protein A16 
99 KRT8 0.190759774 keratin 8, type II 
100 CTSL2 0.19103296  
 
 
Top 100 genes in β4- population 
Rank gene_id 
fold.change. 
β4- / β4+ genename 
1 RPL31P11 39.56084 ribosomal protein L31 pseudogene 11 
2 KRTAP20-2 25.62712 keratin associated protein 20-2 
3 SUMO4 19.8716 small ubiquitin-like modifier 4 
4 RAB11A 19.22263546 RAB11A, member RAS oncogene family 
5 SNORA28 16.47679023 small nucleolar RNA, H/ACA box 28 
6 ZEB2-AS1 14.29556367 ZEB2 antisense RNA 1 
7 POTEM 11.42675277 POTE ankyrin domain family, member M 
8 RMRP 11.027 
RNA component of mitochondrial RNA processing 
endoribonuclease 
9 SCARNA7 10.50824 small Cajal body-specific RNA 7 
10 CXCL14 9.965201093 chemokine (C-X-C motif) ligand 14 
11 POTEJ 9.793759966 POTE ankyrin domain family, member J 
12 CSNK1A1L 9.7768 casein kinase 1, alpha 1-like 
13 SPON2 9.673812413 spondin 2, extracellular matrix protein 
14 SNORA14B 8.895367534 small nucleolar RNA, H/ACA box 14B 
15 FAM78B 8.836337781 family with sequence similarity 78, member B 
16 POTEF 8.173411643 POTE ankyrin domain family, member F 
17 HGF 7.977776299 
hepatocyte growth factor (hepapoietin A; scatter 
factor) 
18 SERPINE1 7.704713281 
serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1), member 1 
19 MSC 7.662533796 musculin 
20 ZEB2 7.239536869 zinc finger E-box binding homeobox 2 
21 MIR3661 7.153655035 microRNA 3661 
22 CXCL12 6.877907642 chemokine (C-X-C motif) ligand 12 
23 ZNF804A 6.832372958 zinc finger protein 804A 
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24 FAM90A2P 6.813 
family with sequence similarity 90, member A2 
pseudogene 
25 CUZD1 6.469748699 CUB and zona pellucida-like domains 1 
26 FLNC 6.447612684 filamin C, gamma 
27 HIST1H4B 6.4476 histone cluster 1, H4b 
28 HS3ST3A1 6.427331867 
heparan sulfate (glucosamine) 3-O-
sulfotransferase 3A1 
29 TGM2 6.396667265 transglutaminase 2 
30 EBF1 6.37322519 early B-cell factor 1 
31 TMEFF2 6.365964799 
transmembrane protein with EGF-like and two 
follistatin-like domains 2 
32 POTEE 6.359760119 POTE ankyrin domain family, member E 
33 MIR3682 6.320083257 microRNA 3682 
34 PIN4P1 6.307404114 
protein (peptidylprolyl cis/trans isomerase) NIMA-
interacting, 4 pseudogene 1 
35 SERPINF1 6.196399774 
serpin peptidase inhibitor, clade F (alpha-2 
antiplasmin, pigment epithelium derived factor), 
member 1 
36 PLAC8L1 6.089834984 PLAC8-like 1 
37 CREB3L1 6.011548445 cAMP responsive element binding protein 3-like 1 
38 TRPC6 5.880595105 
transient receptor potential cation channel, 
subfamily C, member 6 
39 PCDH7 5.857565254 protocadherin 7 
40 MMP3 5.701584203 matrix metallopeptidase 3 
41 PTENP1 5.67822539 
phosphatase and tensin homolog pseudogene 1 
(functional) 
42 SFRP2 5.671937194 secreted frizzled-related protein 2 
43 DCN 5.59704733 decorin 
44 TFPI2 5.457923828 tissue factor pathway inhibitor 2 
45 FOXP1 5.434430939 forkhead box P1 
46 COL5A2 5.394802843 collagen, type V, alpha 2 
47 SNORA51 5.394565631 small nucleolar RNA, H/ACA box 51 
48 DACT1 5.371712803 dishevelled-binding antagonist of beta-catenin 1 
49 SCARNA11 5.314531105 small Cajal body-specific RNA 11 
50 BMPER 5.305486231 BMP binding endothelial regulator 
51 HEG1 5.304122148 heart development protein with EGF-like domains 1 
52 PRAP1 5.24076 proline-rich acidic protein 1 
53 GFAP 5.189984324 glial fibrillary acidic protein 
54 LINC00235 5.051334656 long intergenic non-protein coding RNA 235 
55 FEZ1 4.949002127 fasciculation and elongation protein zeta 1 (zygin I) 
56 PRPS1L1 4.934884 phosphoribosyl pyrophosphate synthetase 1-like 1 
57 
DENND5B-
AS1 4.91194 DENND5B antisense RNA 1 
58 CDRT15 4.88256 CMT1A duplicated region transcript 15 
59 TFAP2B 4.873186417 
transcription factor AP-2 beta (activating enhancer 
binding protein 2 beta) 
60 GPR176 4.869509648 G protein-coupled receptor 176 
61 
INO80B-
WBP1 4.842572365 INO80B-WBP1 readthrough (NMD candidate) 
62 MMP1 4.823947431 matrix metallopeptidase 1 
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63 LAYN 4.813852191 layilin 
64 NNMT 4.762956969 nicotinamide N-methyltransferase 
65 DDX3Y 4.740717564 DEAD (Asp-Glu-Ala-Asp) box helicase 3, Y-linked 
66 COL3A1 4.661040209 collagen, type III, alpha 1 
67 LOXL1 4.645667536 lysyl oxidase-like 1 
68 DPT 4.640355521 dermatopontin 
69 ADAM19 4.591757985 ADAM metallopeptidase domain 19 
70 ESM1 4.590916332 endothelial cell-specific molecule 1 
71 FHL1 4.549355217 four and a half LIM domains 1 
72 PTPRN 4.513944 protein tyrosine phosphatase, receptor type, N 
73 
RPS10-
NUDT3 4.485972758 RPS10-NUDT3 readthrough 
74 EXT1 4.475825975 exostosin glycosyltransferase 1 
75 C9orf53 4.45826  
76 MARCH4 4.456227523 
membrane-associated ring finger (C3HC4) 4, E3 
ubiquitin protein ligase 
77 LOC728875 4.417964747  
78 HIC1 4.417683196 hypermethylated in cancer 1 
79 DACT3 4.394819526 dishevelled-binding antagonist of beta-catenin 3 
80 METRN 4.354512 meteorin, glial cell differentiation regulator 
81 KCNE4 4.348465048 
potassium channel, voltage gated subfamily E 
regulatory beta subunit 4 
82 NPTX1 4.331684174 neuronal pentraxin I 
83 HBEGF 4.277256745 heparin-binding EGF-like growth factor 
84 HAS2 4.242831962 hyaluronan synthase 2 
85 MIR25 4.213524347 microRNA 25 
86 
ARL2-
SNX15 4.206012874 ARL2-SNX15 readthrough (NMD candidate) 
87 NOVA1 4.205469071 neuro-oncological ventral antigen 1 
88 PRG1 4.176908 p53-responsive gene 1 
89 IL13RA2 4.158880367 interleukin 13 receptor, alpha 2 
90 
TSNAX-
DISC1 4.158744 TSNAX-DISC1 readthrough (NMD candidate) 
91 NPPB 4.141444389 natriuretic peptide B 
92 HS3ST3B1 4.136352538 
heparan sulfate (glucosamine) 3-O-
sulfotransferase 3B1 
93 PTEN 4.114100491 phosphatase and tensin homolog 
94 RUNX1T1 4.103495281 
runt-related transcription factor 1; translocated to, 1 
(cyclin D-related) 
95 CNRIP1 4.103266866 cannabinoid receptor interacting protein 1 
96 TOP1P1 4.100549285 topoisomerase (DNA) I pseudogene 1 
97 STEAP1B 4.076097027 STEAP family member 1B 
98 RNF216-IT1 4.040784 RNF216 intronic transcript 1 
99 FMN2 4.025966549 formin 2 
100 EEF1DP3 4.008811645 





Table 3. Summary of RNA-seq of genes downregulated in β4 knockout cells. 
Rank gene id 
fold change 
sg3 / EV 
fold change 
sg4 / EV genename 
1 TSTD1 0.04350126 0.069911745 
thiosulfate sulfurtransferase 
(rhodanese)-like domain containing 1 
2 SPANXA2 0.051349569 0.051349569 SPANX family, member A2 
3 C16orf45 0.07342529 0.064272018 chromosome 16 open reading frame 45 
4 FAM133DP 0.073443954 0.827558717 
family with sequence similarity 133, 
member A pseudogene 
5 CXCR4 0.073926139 0.057124818 chemokine (C-X-C motif) receptor 4 
6 SPINK4 0.075410232 0.191924771 serine peptidase inhibitor, Kazal type 4 
7 NGFR 0.086140919 0.079623097 nerve growth factor receptor 
8 SPANXA2 0.092089193 0.092089014 SPANX family, member A2 
9 EPCAM 0.099203079 0.120440375 epithelial cell adhesion molecule 
10 CCBE1 0.116851125 0.111226787 
collagen and calcium binding EGF 
domains 1 
11 KISS1 0.121346758 0.257111317 KiSS-1 metastasis-suppressor 
12 SCARNA9 0.131348741 0.131348741 small Cajal body-specific RNA 9 
13 HIST1H4A 0.142589889 0.574498084 histone cluster 1, H4a 
14 OR2A20P 0.145343836 0.302905078 
olfactory receptor, family 2, subfamily A, 
member 20 pseudogene 
15 
C10orf32-
AS3MT 0.151792632 0.151764504  
16 
LOC100129
216 0.153774235 0.153774235 beta-defensin 131-like 
17 ZNF521 0.154848462 0.234063645 zinc finger protein 521 
18 OR2A9P 0.159888532 0.159876545 
olfactory receptor, family 2, subfamily A, 
member 9 pseudogene 
19 SCARNA27 0.168141171 0.670204372 small Cajal body-specific RNA 27 
20 NAP1L3 0.171950121 0.31324291 nucleosome assembly protein 1-like 3 
21 RBPMS2 0.173485324 0.202433517 




TNFSF13 0.174179488 1.623951512 TNFSF12-TNFSF13 readthrough 
23 DCN 0.17713751 0.05923473 decorin 
24 IGFBP5 0.179743337 0.1656084 
insulin-like growth factor binding protein 
5 
25 INHBB 0.185578391 0.23093968 inhibin, beta B 
26 ZNF727 0.187631342 0.867948814 zinc finger protein 727 
27 C2orf82 0.193909685 0.394747374 chromosome 2 open reading frame 82 
28 SORCS2 0.19484684 0.433642666 
sortilin-related VPS10 domain 
containing receptor 2 
29 HIST1H3A 0.19598313 0.396238692 histone cluster 1, H3a 
30 SNORA58 0.197098707 0.197098707 small nucleolar RNA, H/ACA box 58 
31 SNORA55 0.204217229 1.013776963 small nucleolar RNA, H/ACA box 55 
32 LGALS12 0.208078264 0.249252292 lectin, galactoside-binding, soluble, 12 
33 FRMD3 0.210432574 1.261265508 FERM domain containing 3 






298 0.21811697 0.412259395 hCG1816373-like 
36 SCGB1B2P 0.218850945 0.682335227 
secretoglobin, family 1B, member 2, 
pseudogene 
37 C19orf73 0.221246658 0.450753757 chromosome 19 open reading frame 73 
38 LOC400927 0.222905072 0.774445985 
TPTE and PTEN homologous inositol 
lipid phosphatase pseudogene 
39 SHANK2 0.226461863 0.287905246 
SH3 and multiple ankyrin repeat 
domains 2 
40 DPYD-AS1 0.227782338 0.802344154 DPYD antisense RNA 1 
41 
RPS10-
NUDT3 0.236315084 0.948134529 RPS10-NUDT3 readthrough 
42 LOC339535 0.239718369 0.195576834  
43 C11orf94 0.245990115 0.245990115 chromosome 11 open reading frame 94 
44 SCARNA6 0.250293093 1.028429291 small Cajal body-specific RNA 6 
45 CRYAB 0.250299439 0.342318396 crystallin, alpha B 
46 MCAM 0.252200635 0.128516192 melanoma cell adhesion molecule 
47 ITGB4 0.255371167 0.275924966 integrin, beta 4 
48 F2RL2 0.256479997 0.261992419 
coagulation factor II (thrombin) 
receptor-like 2 
49 GYPC 0.257663691 0.266597922 glycophorin C (Gerbich blood group) 
50 CBWD5 0.261927415 1.013365068 COBW domain containing 5 
51 PCSK1N 0.262831201 0.413415047 
proprotein convertase subtilisin/kexin 
type 1 inhibitor 
52 PDCL3P4 0.264976447 1.200811281 phosducin-like 3 pseudogene 4 
53 GYG2 0.268174461 0.546234848 glycogenin 2 
54 ASTN1 0.269359997 0.289423557 astrotactin 1 
55 RPS4Y1 0.27005168 0.18999848 ribosomal protein S4, Y-linked 1 
56 RPPH1 0.273742397 0.584716071 ribonuclease P RNA component H1 
57 HLA-DRB4 0.275207359 0.124839581 
major histocompatibility complex, class 
II, DR beta 4 
58 PTGES3L 0.277866041 0.361699879 
prostaglandin E synthase 3 (cytosolic)-
like 
59 PSG1 0.279738817 3.076952994 
pregnancy specific beta-1-glycoprotein 
1 
60 C4orf22 0.280510889 0.516061492 chromosome 4 open reading frame 22 
61 MT1JP 0.280572907 0.641128172 metallothionein 1J, pseudogene 
62 
CKLF-
CMTM1 0.282259749 0.9087251 CKLF-CMTM1 readthrough 
63 IDH1-AS1 0.288881305 0.289558529 IDH1 antisense RNA 1 
64 NCOR1P1 0.289551924 0.289551924 
nuclear receptor corepressor 1 
pseudogene 1 
65 RAB3IL1 0.290038762 1.120807546 
RAB3A interacting protein (rabin3)-like 
1 
66 IGLL3P 0.29010229 0.640255754 




746 0.294879562 0.612377396 uncharacterized LOC100270746 
68 LRP3 0.29535187 0.956468679 
low density lipoprotein receptor-related 
protein 3 
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69 HIGD1C 0.295529234 0.295529234 
HIG1 hypoxia inducible domain family, 
member 1C 
70 DIP2A-IT1 0.295945896 1.000113643 DIP2A intronic transcript 1 
71 
PTGES3L-
AARSD1 0.296339847 0.47612212 PTGES3L-AARSD1 readthrough 
72 ZG16B 0.298211566 0.298211566 zymogen granule protein 16B 
73 HIST1H2BB 0.299100664 1.35017629 histone cluster 1, H2bb 
74 
LOC100505
806 0.30304665 0.415919052  
75 SPANXE 0.30687487 0.306874152  
76 HTRA3 0.311659042 0.311219353 HtrA serine peptidase 3 
77 THY1 0.313556509 0.23963804 Thy-1 cell surface antigen 
78 TERC 0.314465804 1.682530418 telomerase RNA component 
79 TP73-AS1 0.315250251 0.397491492 TP73 antisense RNA 1 
80 SYNGR1 0.316266361 0.555500139 synaptogyrin 1 
81 DAPK1 0.31656718 0.316370303 death-associated protein kinase 1 
82 LINC00173 0.320532503 0.57799114 
long intergenic non-protein coding RNA 
173 
83 DACT3-AS1 0.321700638 0.321700638 DACT3 antisense RNA 1 
84 COL3A1 0.322228195 0.11756305 collagen, type III, alpha 1 
85 MIR186 0.324137158 0.000175196 microRNA 186 
86 SCN5A 0.327542966 0.531201419 
sodium channel, voltage gated, type V 
alpha subunit 
87 LINC00707 0.329058609 0.921487632 
long intergenic non-protein coding RNA 
707 
88 SNORD23 0.329967959 1.476360074 small nucleolar RNA, C/D box 23 
89 MMP2 0.332096761 0.082891432 matrix metallopeptidase 2 
90 SNORA76 0.334330762 1.183125653  
91 NPM2 0.335076625 0.335076625 nucleophosmin/nucleoplasmin 2 
92 TAS2R14 0.335832374 1.248389684 taste receptor, type 2, member 14 
93 ENG 0.336152969 0.439583302 endoglin 
94 SNORA66 0.337839813 0.434350617 small nucleolar RNA, H/ACA box 66 
95 ARHGAP30 0.338493546 0.463041349 Rho GTPase activating protein 30 
96 SOST 0.339875277 0.609284823 sclerostin 
97 HIST1H4C 0.34467218 0.348488932 histone cluster 1, H4c 
98 COL1A2 0.346016848 0.066684619 collagen, type I, alpha 2 
99 LINC00516 0.349443687 0.713864264  
100 
LOC101101







Table 4. Sequences of the primers used in this study. 
qPCR Forward Reverse 
BMP4 5'-AAAGTCGCCGAGATTCAGGG-3' 5'-GACGGCACTCTTGCTAGGC-3' 
CD24 5'-CTCCTACCCACGCAGATTTATTC-3' 5'-AGAGTGAGACCACGAAGAGAC-3' 
E-cad 5’-TTCCAGGAACCTCTGTGATG-3’ 5’-TCTTGGCTGAGGATGGTGTA-3’ 
ETS1 5'-TACACAGGCAGTGGACCAATC-3' 5'-CCCCGCTGTCTTGTGGATG-3' 
GAPDH 5'-CTGGGCTACACTGAGCACC-3' 5'-AAGTGGTCGTTGAGGGCAATG-3' 
HEY1 5'-ATCTGCTAAGCTAGAAAAAGCCG-3' 5'-GTGCGCGTCAAAGTAACCT-3' 
ITGB4 5'-CTCCACCGAGTCAGCCTTC-3' 5'-CGGGTAGTCCTGTGTCCTGTA-3' 
JAG1 5'-GGGGCAACACCTTCAACCTC-3' 5'-CCAGGCGAAACTGAAAGGC-3' 
KRT5 5’-ACATGAACAAGGTGGAGCTG-3’ 5’-AGCTCCGCATCAAAGAACAT-3’ 
KRT14 5’-AACGAGATGCGTGACCAGTA-3’ 5’-TCAGCTCCTCTGTCTTGGTG-3’ 
NOTCH3 5'-CGTGGCTTCTTTCTACTGTGC-3' 5'-CGTTCACCGGATTTGTGTCAC-3' 
OCT4 5’-GAGAAGGATGTGGTCCGAGT-3’ 5’-GTGCATAGTCGCTGCTTGAT-3’ 
P-cad 5'-TGGAGATCCTTGATGCCAATGA-3' 5'-GCGTCCAGATCAGTGACCG-3' 
PTH1R 5'-AGTGCGAAAAACGGCTCAAG-3' 5'-GATGCCTTATCTTTCCTGGGC-3' 
PTHrP 5-AAGGTGGAGACGTACAAAGAGC-3' 5'-CAGAGCGAGTTCGCCGTTT-3' 
TP63 5'-GGACCAGCAGATTCAGAACGG-3' 5'-AGGACACGTCGAAACTGTGC-3' 
VEGF-A 5'-AGGGCAGAATCATCACGAAGT-3' 5'-AGGGTCTCGATTGGATGGCA-3' 
   CRISPR Oligo 1 Oligo 2 
sg3 CACCGTTGTCCAGATCATCGGACA AAACTGTCCGATGATCTGGACAAC 












Generate β4 Reporter Mouse Using CRISPR 
 
Abstract 
To better study the role of integrin β4 in tumor formation and track the β4+ 
population during tumor progression, I made a β4 reporter mouse using CRISPR. 
I inserted a p2A-mCherry cassette before the stop codon of the ITGB4 gene, and 
first tested the design strategy in vitro in NMuMG cells. 
 
Introduction 
To better study the role of the β4+ population in breast tumors, it will be helpful if 
we can track the β4+ population during tumor progression. Previous models 
suggest that tumor cells need to undergo EMT to drive tumor invasion and break 
away from the primary tumor site. Cells will then undergo MET at the secondary 
site and form metastasis (Thiery et al., 2009). However, there is no clear 
evidence showing that EMT and MET are real and necessary during metastasis. 
Studies from the Ewald group show that the leader cells that drive tumor invasion 
are a basal epithelial population, not the cells that undergo EMT (Cheung et al., 
2013; Shamir et al., 2014). Recently, two back-to-back studies showed that EMT 
is not required for metastasis in lung and pancreatic cancer (Fischer et al., 2015; 
Zheng et al., 2015). These studies show that there is a basal epithelial population 
that drive tumor invasion, and epithelial tumor cells can intravasate into the blood 
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system and form metastasis at the secondary site without undergoing EMT and 
MET. To show how β4 is involved in this process and localize the β4+ population, 
I wanted to make a β4 reporter mouse and cross it with breast tumor model so 
that I can track the β4+ population during tumor progression. 
 
Homozygous β4 deletion mice die shortly after birth (Dowling et al., 1996; van 
der Neut et al., 1996; 1999b). Our lab showed that β4 is important for mammary 
gland development, and even heterozygotes have defects in the mammary gland 
(Li et al., 2015). Thus, this reporter mouse design strategy has to keep the ITGB4 
gene intact after inserting mCherry. Moreover, to avoid blocking the ligand-
binding site of β4, it is better to add the reporter gene at the C-terminus of β4. 
However, our lab showed that fusing GFP to the C-terminus of β4 drives β4 into 
nucleus. Thus, I added a p2A self-cleaved peptide between ITGB4 and mCherry. 
After translation, p2A will be cleaved automatically so that β4 and mCherry will 
be separated with β4 going to the cell surface while mCherry stays in the 
cytoplasm (Kim et al., 2011b). Thus, my design is to insert the p2A-mCherry 
cassette right before the TGA stop codon of ITGB4 without affecting the 
sequence of ITGB4. 
 
Results and Discussion 
Initially I designed 4 sgRNAs near the TGA stop codon of the ITGB4 gene. To 
test the efficiency of the 4 sgRNAs, I cloned the 4 sgRNAs into PX458 vector and 
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transfected them into NMuMG cells. The transfection efficiency was about 10%. I 
sorted GFP+ cells and did a SURVEYOR Assay (Fig 5B). I chose the sgRNA #2 
that cut 3bp after the stop codon of ITGB4 since it would give me higher 
homology recombination (HR) efficiency. To make the plasmid donor for HR, I 
PCR amplified ITGB4 2kb left homology arm and ITGB4 3kb right homology arm 
from the genomic DNA of NMuMG cells, and cloned them flanking the p2A-
mCherry cassette (Fig 5A).  
 
I transfected PX330-sgRNA and plasmid donor together into NMuMG cells, and 
used PX330 vector alone with plasmid donor as negative control. I got 0.3% 
mCherry-positive cells without any selection 5 days post-transfection (Fig 5C). To 
confirm the correct insertion of the p2A-mCherry cassette, I designed a pair of 
primers with the Forward primer outside of the 2kb ITGB4 left homology arm and 
the Reverse primer inside of the mCherry sequence (Fig 5A). I did PCR with 
genomic DNA extracted from post-transfected NMuMG cells before mCherry 
sorting. I saw the correct size band of about 2.5kb in the sgRNA cells but not in 
the negative control cells (Fig 5D). I cut the 2.5kb band and did sequencing to 
make sure p2A-mCherry was inserted before TGA stop codon correctly (Fig 5D).  
 
Western blot showed that the size and expression of integrin β4 is not affected by 
mCherry insertion in sorted mCherry-positive cells, and mCherry mRNA is also 
detected (Fig 5E). I also tested my design strategy and HR frequency in E14 
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cells which is a normal mouse embryonic stem cell line, and saw the similar 
results (data not shown). After I confirmed the CRISPR design successfully in 
vitro with cell lines, I made the mouse in BL6 background at Jackson Lab, 
collaborating with Dr. Steve Murray. There is one potentially correct mouse, and 
we’ll do further examination to confirm it. 
 
Materials and Methods 
Generating sgRNAs Expressing Vector and plasmid donor. Bicistronic 
expression vector (PX458 or PX330) expressing Cas9 and sgRNA (Cong et al., 
2013) were digested with Bbsl and treated with Antarctic Phosphatase, and the 
linearized vector was gel purified. A pair of oligos for each targeting site (Table 5) 
was annealed, phosphorylated, and ligated to linearized vector. For plamid donor, 
Nanog-2A-mCherry plasmid (Addgene) was cut at BamHI/NheI on the left and 
PacI/NotI on the right. ITGB4 2kb left homologous arm and ITGB4 3kb right 
homologous arm was PCR amplified from the genomic DNA of NMuMG cells and 
cloned into digested Nanog-2A-mCherry on each side, respectively. 
 
Cell Culture and Transfection. NMuMG cells were purchased from ATCC and 
maintained as described (Chang et al., 2013). PX458 vector (Addgene) cloned 
with indicated sgRNAs were transfected into NMuMG cells to examine to 
efficiency of sgRNAs. PX330 vector (Addgene) cloned with indicated sgRNAs 
					48	
and plasmid donor were transfected in NMuMG cells to test the homology 
recombination in vitro.   
 
Surveyor Assay. Genomic DNA from NMuMG cells transfected with indicated 
sgRNAs in the PX458 vector were extracted and surveyor assay was performed 
as described by (Guschin et al., 2010). Sequences of the primers used for 
suveryor assay were provided in Table 5. 
 
Immunoblotting and qPCR. Cells were extracted in RIPA (50mM Tris-HCL [pH 
7.4], 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1mM PMSF, and 
protease inhibitors). The proteins were separated by SDS-PAGE and 
immunoblotted using antibodies for actin (Sigma-Aldrich) and β4 (505) 
(Rabinovitz et al., 1999). For qPCR, RNA isolation was done with the 
NucleopSpin RNA kit (Macherey-Nagel) and 1ug of total RNA was used to 
produce cDNAs using Roche First strand synthesis kit (Roche). qPCR was 
performed using a SYBR green (Applied Biosystems) master mix as described 









shown at the bottom. (C) mCherry expression in NMuMG cells transfected with 
PX330-sgRNA2 and plasmid donor. (D) PCR checking the correct insertion of 
p2A-mCherry. Primers are shown in (A). Sequencing result of the 2.5kb band is 




















Table 5. Sequences of the primers used in this study. 
qPCR Forward Reverse 
GAPDH 5'-CTGGGCTACACTGAGCACC-3' 5'-AAGTGGTCGTTGAGGGCAATG-3' 
ITGB4 5'-CTCCACCGAGTCAGCCTTC-3' 5'-CGGGTAGTCCTGTGTCCTGTA-3' 




Surveyor 5'-ATCCTGACTGACGGATCTGCC-3' 5'-AAGTGCAGAACAAAAGGCTGGG-3' 
mCherry
Seq 5'-TAGGCCTCCCTCCTATCTGGGAAG-3' 5'-TCCTCGAAGTTCATCACGCGCT-3' 
 CRISPR Oligo 1 Oligo 2 
sgRNA1 5'-CACCGTGACCCAGGAATTCGTGACC-3' 5'-AAACGGTCACGAATTCCTGGGTCAC-3' 
sgRNA2 5'-CACCGCTGGGGCGCGGGGGAGGTTC-3' 5'-CACCGTGACCCAGGAATTCGTGACC-3' 
sgRNA3 5'-CACCGAGGAAGAAGGCGCTAGGAG-3' 5'-AAACCTCCTAGCGCCTTCTTCCTC-3' 
sgRNA4 5'-CACCGAGAGAGCCACTGGCCGTTA-3' 5'-AAACTAACGGCCAGTGGCTCTCTC-3' 
 Cloning Sequence 
BamHI-
























EMT and CSC 
A CD24-CD44+ population has been identified as CSCs in breast cancer by 
showing that this population alone is sufficient to form new tumors in vivo (Al-Hajj 
et al., 2003). EMT generates cells with stem-cell properties that express 
mesenchymal markers and are CD24-CD44+ (Mani et al., 2008). In the past 
decade, this EMT model has received lots of interest in the field. At the primary 
tumor site, normal epithelial cells undergo EMT and become mesenchymal-like 
with CSC properties, which is important for tumor initiation. According to this 
model, cells that undergo EMT can intravasate into the blood system and 
extravasate to arrive at the secondary site. Upon arrival, these cells need to 
undergo MET to form metastasis (Thiery et al., 2009). However, no clear 
evidence shows that EMT and MET processes are real and necessary for tumor 
progression and metastasis.  
 
There are two CSC models during tumor metastasis. Both models propose that 
cells need to undergo EMT for invasion and MET to form colonization at the 
secondary site. In the first model, CSCs are motile and circulate through blood 
system (Tsai et al., 2012). In the second model, EMT factors need to be 
repressed for cells to gain CSC properties. It proposes that CSCs are stationary 
and exist in both primary and secondary site all the time (Ocaña et al., 2012). 
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However, recently there are two back-to-back papers indicating that EMT is not 
required for metastasis in lung cancer and pancreatic cancer, respectively 
(Fischer et al., 2015; Zheng et al., 2015). Studies also show that it is a basal 
epithelial population that drives tumor invasion, which contradicts the idea that 
cells need to undergo EMT to break away from the primary site (Thiery et al., 
2009).  
 
Intratumor heterogeneity and cell cooperation 
Cancer genome sequencing studies indicate that there are multiple 
subpopulations that have distinct molecular properties within a single breast 
cancer (Ding et al., 2010; Navin et al., 2011; Nik-Zainal et al., 2012; Shah et al., 
2009). It is known that tumor cells need to interact with the microenvironment and 
communicate with the surrounding cells of various types, such as endothelial 
cells, mesenchymal stem cells, cancer-associated fibroblasts and immune cells 
(Ungefroren et al., 2011).  
 
However, within the tumor cells, different subpopulations also need to interact 
with each other. In the view of clonal evolution model, subpopulations are 
considered as competitors to others that the certain subpopulation will gain 
growth advantage over others after certain mutations. At some times, tumor cells 
also need to cooperate. By injecting EMT cells and non-EMT cells separately or 
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together, Tsuji et al. show that both EMT and non-EMT breast tumor cells are 
needed for lung metastasis and they work together (Tsuji et al., 2009). Cleary et 
al. show that in Wnt-driven mammary cancers, both basal Hras mutant and 
luminal Hras wild-type subpopulations are required for tumor formation (Cleary et 
al., 2014). Yamamoto et al. also showed that CSCs and non-CSCs interact with 
each other through paracrine signaling (Yamamoto et al., 2013). In this study, 
they found that non-CSCs produce JAG1 while CSCs express Notch3 receptor 
so that non-CSCs can regulate CSCs through paracrine Notch signaling by 
providing JAG1 ligand.   
 
Integrin β4 in breast tumor metastasis 
In breast cancer, β4 has been shown to switch from linking cytokeratin to actin 
and redistribute to cell protrusions (Lipscomb and Mercurio, 2005; Rabinovitz and 
Mercurio, 1997; Rabinovitz et al., 1999). In addition LM332, the ligand of β4, is 
enriched at the invading front of several carcinomas (Kim et al., 2011a; Pyke et 
al., 1995; Xue et al., 2011).  Given the important role that β4 plays for tumor 
invasion, I think it is very likely that β4+ cells associated with a basal epithelial 
program in tumor are the cells that at the invading front to drive tumor invasion. 
These cells don’t undergo EMT or MET, and they stay epithelial through tumor 
metastasis. To examine this hypothesis, I made a β4 reporter mouse so that I 
can cross it with breast tumor models and track β4+ cells during tumor 
progression and metastasis. 
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Expression of integrin β4 has been found to correlate with highly metastatic cells 
{Dedhar:1993ww, Cimino:1997uv}. Periostin, an integrin β4 ligand, is an 
extracellular matrix protein induced in the lung stroma and provides a niche to 
support metastatic colonization (Baril et al., 2006; Malanchi et al., 2012). This 
could be the way that β4+ tumor cells migrate to the metastatic site and form 
metastasis. Interestingly, a recent study linked integrin β4 to the exosomes in 
tumor metastasis (Hoshino et al., 2015). Exosomes are released from tumor cells 
into the microenvironment of the primary site and have been found to play roles 
in tumor invasion and metastasis (Lowry et al., 2015). This study shows that 
exosomes have distinct integrin expression patterns, in which the integrin α6β4 
and α6β1 are associated with lung metastasis (Hoshino et al., 2015). The data 
suggests that exosomes expressing integrins will first travel to secondary site 
and secrete various proteins they bring to create a metastasis niche. Tumor cells 
will then migrate to that secondary site to form metastasis. These studies 
suggest a role for integrin β4 in creating the metastatic niche at the secondary 
site and supporting metastatic colonization.  
 
Integrin β4 and PTHrP 
The role of PTHrP as a mediator of osteolytic bone metastasis in breast cancer 
has been extensively studied in bone metastasis. PTHrP is a paracrine factor 
that is expressed by tumor cells and is secreted to the bone microenvironment, 
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which together with cytokines and growth factors play a negative impact on 
osteroblast function and lead to the destruction of bone. PTHrP produced by 
breast cancer cells enhaces osteoclastic activity via the expression of 
osteoblastic receptor activator of nuclear factor kappa B ligand (RANKL), 
vascular endothelial growth factor (VEGF) and matrix metalloproteinase-13 
(MMP13) (Chen et al., 2010; Ibaragi et al., 2010; Isowa et al., 2010; Zhang et al., 
2010). PTHrP is also important for mammary tumor formation and invasion 
(Lowry et al., 2015). This thesis study also discussed the possibility that β4 
regulation of PTHrP is important for tumor formation by regulating CSCs in a 
non-cell-autonomous manner. We showed in a couple of different systems that 
PTHrP is expressed by β4+CD24+CD44+ non-CSCs that have basal epithelial 
markers while its receptor PTH1R is associated with β4-CD24-CD44+ CSCs. 
These two populations interact with each other through PTH1R paracrine 
signaling. This work also shows that integrin β4 can regulate PTHrP expression 
which can be directly affected by the ligation of integrin α6β4 when culturing cells 
on laminins. 
 
Conclusion Remarks and Perspectives 
This study investigates the role of integrin β4 in breast tumor formation and the 
mechanism involved. It shows that β4 is heterogeneously expressed in breast 
tumors and it is important for tumor formation though it is not directly expressed 
by CSCs. I characterized β4+ and β4- subpopulations in breast tumors and 
					58	
investigated how they may cooperate with each other during tumor progression. 
My data shows that β4 is expressed by a basal epithelial CD24+CD44+ 
population which are likely to be the leader cells at the invading front to drive 
tumor invasion. β4+ non-CSCs can regulate β4- CSC functions through paracrine 
signaling, such as Notch signaling and PTH1R signaling. Further experiments 
needed to be done to demonstrate the interactions between β4+ and β4- 
populations and show that these interactions are essential for stem cell 
properties. β4+ and β4- populations can be isolated and labeled before co-culture 
to examine the stem cell properties as well as signalings and downstream genes 
in β4- population. β4+ and β4- populations can also be cultured in transwell plates 
to see if the physical interactions between the two populations are needed to 
maintain the CSC properties of β4- population.  
 
I also investigated the possibility of PTH1R signaling involved in β4 regulation on 
CSCs. More experiments need to be done to confirm the regulation of integrin β4 
on PTHrP and study the mechanism involved. It is also important to show that 
PTH1R signaling is critical for CSC functions. This can be studied by knocking 
down PTH1R in breast cancer cell lines and examine CSC properties either by 
mammosphere formation assay or tumor initiation assay in vivo. I also showed 
that β4 deletion in SUM-159 cells affected the CSC function of CD24-CD44+ 
population to give rise to CD24+CD44+ population. Further examination is needed 
to check the changes in CD24-CD44+ population after β4 deletion at the 
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molecular level. Finally, to better study the role of integrin β4 in tumor 
progression and metastasis, the β4 reporter mouse I’m making will be a very 
useful tool.  The β4 reporter mouse can be crossed with breast tumor model so 
that the role of β4+ population and the interactions between β4+ and β4- 
populations can be better studied. Moreover, β4+ population can also be tracked 
during tumor progression from the primary tumor site to metastatic site to study 
the role of β4 in tumor metastasis. One important question is that whether β4+ 
population travel to the metastatic site or the β4- tumor cells from primary tumor 
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